Speaker Profile
M.D., Clinical Professor of Medicine, UCSF/Arc Isntitute
Biography
William K. Oh, M.D., is currently the Director of Precision Medicine at Yale Cancer Center and a Professor of Medicine (Medical Oncology) at Yale School of Medicine, roles he assumed in October 2024. As part of a newer initiative at Yale, he is focused on building a cohesive program inprecision cancer medicine that integrates basic and translational science,clinical trials, and Smilow Cancer Hospitals Precision Medicine Tumor Board. A central goal of his work is to increase the routine use ofmolecular and genetic testing for all cancer patients to improve outcomes. Dr. Oh is also dedicated to delivering multidisciplinary care for prostate cancer patients, a priority he has maintained for over 25 years. He has been recognized as a Top Doctor by Castle Connolly, New York Magazine, and Super Doctors. Additionally, he continues his commitment to teaching andadvancing research in the field.Previously, Dr. Oh was a Clinical Professor of Medicine at Icahn School of Medicine. He is an internationally recognized medical oncologist withextensive experience in clinical and translational research, holding leadership roles in both academia and industry. He has authored more than 350 articles, reviews, books, and book chapters related to genitourinary cancers. Dr. Oh has conducted numerous clinical cancer trials and served in key invited roles for ASCO, ACS, and AUA. He has also held the position of Chief Medical Officer for Sema4, a genomics and health intelligence company, as well as the Prostate Cancer Foundation.
Session Abstract – PMWC 2027 Silicon Valley
Track Chair:
Razelle Kurzrock, Emory
PMWC Award Ceremony
• Antoni Ribas, UCLA Health (Luminary)
Featured Speakers
• Antoni Ribas, UCLA Health
• Gerold Meinhardt, Daiichi Sankyo
• Katy Rezvani, MD Anderson
• Javad Shahidi, BeOne
• Alicia Zhou, Cancer Research Institute
• Oren Gilad, Aprea Therapeutics
• Adam Palmer, UNC
• Trever Bivona, UCSF
• Laura Volta, Penn Medicine
• Vivek Subbiah, Stanford
• Mark Stewart, Friends of Cancer Research
Precision Immunotherapy After PD-1
Cells, bispecifics, ADCs, and new combination logic after checkpoint failure.
Biomarkers That Matter
Selecting patients for immunotherapy and targeted therapy with decision-grade biomarkers.
Resistance Biology & Adaptive Combination Strategies
How tumors adapt, and how to sequence therapy around that biology.
Which Immune Cells Can Be Programmed In Vivo?
The next wave of immune-cell engineering and where it may matter first.
Rare Cancers, Basket Trials & N-of-1 Playbooks
Moving from histology-agnostic evidence to individualized precision oncology.
PMWC Hall of Impact
Previous Speakers Include
Nobel laureates, technology founders, regulators, CEOs and scientific pioneers who have taken the PMWC stage.
